SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001641172-25-002904 from Caring Brands, Inc. (CABR)

Caring Brands, Inc.
Date: April 7, 2025 · CIK: 0002020737 · Accession: 0001641172-25-002904

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-285964

Referenced dates: April 2, 2025

Date
March 20, 2025
Author
Chief
Form
CORRESP
Company
Caring Brands, Inc.

Letter

Securities and Exchange Commission Division of Corporate Finance Registration Statement on Form S-1 Filed March 20, 2025 File No. 333-285964

Re: Caring Brands, Inc.

Dear Mr. Augustin and Ms. Park:

Please find below our responses to the questions raised by the staff (the " Staff ") of the Securities and Exchange Commission (the " Commission ") in its letter of comments dated April 2, 2025 (the " Comment Letter") relating to the registration statement on Form S-1, which was filed with the Commission by Caring Brands, Inc. (the " Company " or " we ") on March 20, 2025.

The Company's responses are numbered to correspond to the Staff's comments. For your convenience, each of the Staff's comments contained in the Comment Letter has been restated in bold .

We have also updated the Registration Statement on Form S-1 (" Registration Statement ") which is submitted to the Commission simultaneously together with this letter.

Registration Statement on Form S-1 filed March 20, 2025

Index to consolidated financial Statements page F-1

1. As the financial statements are now as of a date after the merger and given the nature of the two companies and the transaction, it appears appropriate to include one set of consolidated financial statements for the combined entity. In presenting operations prior to the merger, we remind you that the determination of the accounting acquirer under ASC 805 is different from the determination of whether there is a predecessor entity pursuant to Rule 405 of Regulation C. Because of the insignificant operations of CBI NV and the change in focus to the ongoing business of CBI FL, it appears that CBI FL would be the predecessor entity prior to the September 2024 transaction. As a result, we would expect the premerger historical financial statements of the consolidated entity to be the historical financial statements of CBI FL only. The premerger results of operations of CBI NV should no longer be presented. The pro forma financial statements would appear to no longer be required. Please revise the financial statements as necessary or provide a comprehensive analysis of how you determined that CBI FL would not be the predecessor entity pursuant to Rule 405 of Regulation C.

Response : The Company has revised its financial statements to reflect the appropriate Predecessor and Successor information consistent with the comment of the staff. The Company referred to Section 1170 of the SEC Reporting Manual to make its modifications.

In addition, we have added language as to the Company's belief with respect to the statistical significance of the p-values in the clinical studies discussion on page 42. Should you have any questions regarding the foregoing, please do not hesitate to contact me or our counsel with any questions or comments regarding this correspondence on the revised and updated Registration Statement.

Very
truly yours,
By:
/s/
Glynn Wilson

Show Raw Text
CORRESP
 1
 filename1.htm

 April
7, 2025

 Securities
and Exchange Commission

 Division
of Corporate Finance

 100
F Street, NE

 Washington,
D.C. 20549

 Attn:
Mr. Robert Augustin and Ms. Jane Park

 Re:
Caring Brands, Inc.

 Registration
Statement on Form S-1

 Filed
March 20, 2025

 File
No. 333-285964

 Dear
Mr. Augustin and Ms. Park:

 Please
find below our responses to the questions raised by the staff (the " Staff ") of the Securities and Exchange Commission
(the " Commission ") in its letter of comments dated April 2, 2025 (the " Comment Letter") relating
to the registration statement on Form S-1, which was filed with the Commission by Caring Brands, Inc. (the " Company "
or " we ") on March 20, 2025.

 The
Company's responses are numbered to correspond to the Staff's comments. For your convenience, each of the Staff's comments
contained in the Comment Letter has been restated in bold .

 We
have also updated the Registration Statement on Form S-1 (" Registration Statement ") which is submitted to the Commission
simultaneously together with this letter.

 Registration
Statement on Form S-1 filed March 20, 2025

 Index
to consolidated financial Statements page F-1

 1.
 As
 the financial statements are now as of a date after the merger and given the nature of the two companies and the transaction, it
 appears appropriate to include one set of consolidated financial statements for the combined entity. In presenting operations prior
 to the merger, we remind you that the determination of the accounting acquirer under ASC 805 is different from the determination
 of whether there is a predecessor entity pursuant to Rule 405 of Regulation C. Because of the insignificant operations of CBI NV
 and the change in focus to the ongoing business of CBI FL, it appears that CBI FL would be the predecessor entity prior to the September
 2024 transaction. As a result, we would expect the premerger historical financial statements of the consolidated entity to be the
 historical financial statements of CBI FL only. The premerger results of operations of CBI NV should no longer be presented. The
 pro forma financial statements would appear to no longer be required. Please revise the financial statements as necessary or provide
 a comprehensive analysis of how you determined that CBI FL would not be the predecessor entity pursuant to Rule 405 of Regulation
 C.

 Response :
The Company has revised its financial statements to reflect the appropriate Predecessor and Successor information consistent
with the comment of the staff. The Company referred to Section 1170 of the SEC Reporting Manual to make its modifications.

 In
addition, we have added language as to the Company's belief with respect to the statistical significance of the p-values
in the clinical studies discussion on page 42. Should you have any questions regarding the foregoing, please do not hesitate to
contact me or our counsel with any questions or comments regarding this correspondence on the revised and updated Registration Statement.

 Very
 truly yours,

 By:
 /s/
 Glynn Wilson

 Name:
 Glynn
 Wilson

 Chief
 Executive Officer